Welcome to This Week in Ophthalmology. This week we're covering 9 notable papers spanning new therapeutic approaches in retina, refinements in managing uveitis, and how new technology is changing risk stratification and diagnosis. Let's dive in.

This week's papers:

1. Subretinal Gene Therapy for X-Linked Retinoschisis. — The New England journal of medicine 2026
2. Polygenic risk impacts lifetime risk and prognosis of glaucoma. — Ophthalmology 2026
3. Quantitative Swept-Source Optical Coherence Tomography Angiography Indicators of Neurovascular Dysfunction in Alzheimer Disease. — JAMA ophthalmology 2026
4. 12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial. — The British journal of ophthalmology 2026
5. Anti-Adalimumab Antibodies in Patients with Inflammatory Ocular Diseases: Incidence and Clinical Outcomes. — American journal of ophthalmology 2026
6. Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis. — Retina (Philadelphia, Pa.) 2026
7. Evaluating reasoning in multimodal large language models for ophthalmology: a bilingual benchmark study using clinical vignettes and imaging. — The British journal of ophthalmology 2026
8. Herpesvirus Retinitis by Immune Status: Clinical Phenotypes and Predictors of Retinal Detachment and Severe Visual Impairment. — Ophthalmology. Retina 2026
9. Development of diagnostic criteria for Behçet's uveitis in a Chinese population. — The British journal of ophthalmology 2026

Listen at AudioScholar